findmyKOL
Clinical trialNCT00006459CompletedPhase 3Interventional

Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer

SponsorEli Lilly and CompanyBreast Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

31 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Comprehensive Cancer Institute of Huntsville

    Huntsville, Alabama, United States

  • Little Rock Hematology-Oncology Associates

    Little Rock, Arkansas, United States

  • Pacific Coast Hematology/oncology Medical Group

    Fountain Valley, California, United States

  • Office of Alex J.P. Makalinao

    Los Angeles, California, United States

  • Hematology/oncology Group

    Santa Rosa, California, United States

  • University of Colorado Cancer Center

    Denver, Colorado, United States

  • Danbury Internal Medicine

    Danbury, Connecticut, United States

  • Comprehensive Cancer Care Specialists of Boca Raton

    Boca Raton, Florida, United States

  • Mercy Hospital

    Miami, Florida, United States

  • Mountain States Tumor Institute

    Boise, Idaho, United States

  • Memorial Medical Center

    Springfield, Illinois, United States

  • Carle Cancer Center

    Urbana, Illinois, United States

  • Indiana Community Cancer Care, Inc.

    Indianapolis, Indiana, United States

  • Cancer Health Associates

    Michigan City, Indiana, United States

  • North Mississippi Hematology and Oncology Associates, Ltd.

    Tupelo, Mississippi, United States

  • St. John'S Mercy Medical Center

    St Louis, Missouri, United States

  • Apn-Impath Research Corporation

    Fort Lee, New Jersey, United States

  • Overlook Hospital

    Summit, New Jersey, United States

  • Hemoncare, P.C.

    Brooklyn, New York, United States

  • Interlakes Oncology/hematology Pc

    Rochester, New York, United States

  • N.W. Carolina Oncology & Hematology, P.A.

    Hickory, North Carolina, United States

  • Oklahoma Oncology Inc.

    Tulsa, Oklahoma, United States

  • Rittenhouse Hematology/oncology

    Philadelphia, Pennsylvania, United States

  • South Carolina Oncology Associates

    Columbia, South Carolina, United States

  • Office of C. Michael Jones

    Germantown, Tennessee, United States

  • Boston Baskin Cancer Group, University Tennessee Oncology/hematology Group

    Memphis, Tennessee, United States

  • University of Tennessee, Memphis

    Memphis, Tennessee, United States

  • Arlington Cancer Center

    Arlington, Texas, United States

  • Southwest Regional Cancer Center

    Austin, Texas, United States

  • Intermountain Hematology/oncology Associates, Inc.

    Salt Lake City, Utah, United States

  • Northern Virginia Oncology Group, P.C.

    Fairfax, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jul 2000
Primary completion
Completion
31 Oct 2005
Last update posted
7 Jun 2012
Registered enrollment
Registry id
NCT00006459

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.